| Spherix Announces First Quarter 2010 Financial Results (PR Newswire) Spherix Incorporated , an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the three months ended March 31, 2010. us.rd.yahoo.com |
Dr. Reddy's Profit Retreats 14% Indian drug maker Dr. Reddy's reported a steeper-than-expected 14% drop in first-quarter consolidated net profit, dragged down mainly by lower sales in the North American market. online.wsj.com |
LabCorp Announces $250 Million Stock Repurchase Program (Business Wire) BURLINGTON, N.C.----Laboratory Corporation of AmericaВ® Holdings today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an additional aggregate of $250 million of its Common Stock from time-to-time. us.rd.yahoo.com |
Immunogen's T-DM1 Gets Presidential Treatment Ohad Hammer submits:Immunogen (IMGN) is still trying to recuperate from the controversial rejection of T-DM1's accelerated approval filing. The message Immunogen was trying to convey is that nothing has changed in terms of T-DM1's long term potential. According to the company, the FDA's problem was not with the drug's stellar activity but the patient population enrolled on the trial. In just over a week from now, it could have the data to prove it.Although the next potential filing is expected only in 2012 based on an ongoing phase III trial (EMILA study), T-DM1 will have two important data read-outs at next month's ESMO conference. The first is a phase II study where it is compared to chemotherapy+ Herceptin, the current standard of care for 1st line breast cancer patients. As I reviewed last month, expectations from this trial are high given Roche's (RHHBY.PK) decision to start a pivotal trial based on a similar trial design.Complete Story » seekingalpha.com |
Trius to Present at San Diego Biotechnology Network Event [PR Newswire] - Trius Therapeutics, Inc. announced today that John Finn, Ph.D., Chief Scientific Officer at Trius Therapeutics, will present "Innovative Antibacterial Drugs by Design; The Trius Therapeutics Story" at the San Diego Biotechnology Network event taking place on October 26, 2010 from 5:30-9:30 p.m. us.rd.yahoo.com |